PriceTargets.com logo

Profound Medical - PROF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.63
  • Forecasted Upside: 31.51%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$9.60 As of 09/27/2023 01:00 AM ET
▼ -0.42 (-4.19%)

This chart shows the closing price for PROF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Profound Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PROF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PROF

Analyst Price Target is $12.63
▲ +31.51% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Profound Medical in the last 3 months. The average price target is $12.63, with a high forecast of $20.00 and a low forecast of $6.50. The average price target represents a 31.51% upside from the last price of $9.60.

This chart shows the closing price for PROF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Profound Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2023
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/18/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$20.00Low
8/4/2023Raymond JamesDowngradeStrong-Buy ➝ OutperformLow
6/5/2023Raymond JamesBoost TargetStrong-Buy$17.00 ➝ $20.00Low
3/21/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$5.50 ➝ $10.00Low
3/8/2023Raymond JamesBoost TargetStrong-Buy$15.00 ➝ $17.00Low
1/6/2023Lake Street CapitalBoost Target$7.00 ➝ $14.00Low
11/4/2022Alliance Global PartnersLower TargetBuy ➝ Buy$12.50 ➝ $6.50Low
11/4/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$15.00Low
9/28/2022Raymond JamesSet TargetOutperform$15.00Low
8/8/2022Raymond JamesLower TargetOutperform$17.50 ➝ $15.00Low
7/18/2022Raymond JamesLower TargetOutperform$22.00 ➝ $17.50Low
5/10/2022Alliance Global PartnersLower TargetBuy$16.25 ➝ $12.00Medium
5/10/2022Raymond JamesSet TargetOutperform$22.00Medium
4/25/2022Raymond JamesSet TargetOutperform$22.00Low
3/21/2022Raymond JamesLower TargetOutperform$23.00 ➝ $22.00Medium
3/7/2022CowenLower TargetOutperform$28.00 ➝ $14.00High
3/2/2022Raymond JamesSet TargetOutperform$23.00Low
2/22/2022Raymond JamesDowngradeStrong-Buy ➝ Outperform$28.00 ➝ $23.00High
1/20/2022Raymond JamesSet TargetStrong-Buy$28.00High
1/19/2022Raymond JamesBoost TargetStrong-Buy$35.00Low
12/2/2021Raymond JamesSet TargetStrong-Buy$28.00High
11/8/2021Raymond JamesLower TargetStrong-Buy$30.00 ➝ $28.00Low
10/27/2021Raymond JamesLower TargetStrong-Buy$36.00 ➝ $30.00Medium
9/30/2021Raymond JamesSet TargetStrong-Buy$36.00High
9/29/2021Raymond JamesBoost TargetStrong-Buy$46.00High
8/26/2021Raymond JamesSet TargetStrong-Buy$36.00Low
8/5/2021Raymond JamesSet TargetStrong-Buy$36.00Low
7/1/2021Raymond JamesSet TargetStrong-Buy$36.00Low
6/30/2021Raymond JamesBoost TargetStrong-Buy$44.50Low
6/21/2021Raymond JamesReiterated RatingStrong-Buy$36.00Low
5/13/2021Alliance Global PartnersLower TargetBuy$28.25 ➝ $21.00Low
5/10/2021Raymond JamesSet TargetStrong-Buy$36.00High
5/4/2021Raymond JamesBoost TargetStrong-Buy$34.00 ➝ $36.00Medium
3/29/2021Raymond JamesReiterated RatingStrong-Buy$34.00Low
3/10/2021Raymond JamesReiterated RatingStrong-Buy$34.00Low
3/4/2021Leede Jones GabReiterated RatingBuyMedium
1/25/2021Lake Street CapitalBoost Target$27.00 ➝ $32.00Medium
1/7/2021Alliance Global PartnersBoost TargetBuy$20.25 ➝ $28.25N/A
9/15/2020Jefferies Financial GroupInitiated CoverageBuyHigh
9/10/2020Lake Street CapitalInitiated CoverageBuy$22.00High
8/7/2020Alliance Global PartnersReiterated RatingBuy$15.00 ➝ $18.00High
7/31/2020Raymond JamesBoost TargetStrong-Buy$38.00 ➝ $43.00High
6/26/2020Raymond JamesBoost TargetStrong-Buy$35.00 ➝ $38.00Low
4/7/2020MackieDowngradeBuy ➝ HoldHigh
4/1/2020CowenInitiated CoverageOutperform$15.00Medium
1/27/2020Raymond JamesUpgradeOutperform ➝ Strong-BuyLow
11/8/2019Echelon Wealth PartnersReiterated RatingBuyLow
(Data available from 9/27/2018 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Profound Medical logo
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, palliative pain treatment of bone metastases, and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $9.60
Low: $9.46
High: $10.20

50 Day Range

MA: $9.80
Low: $7.91
High: $12.93

52 Week Range

Now: $9.60
Low: $3.10
High: $15.49

Volume

15,084 shs

Average Volume

26,949 shs

Market Capitalization

$205.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Profound Medical?

The following Wall Street sell-side analysts have issued reports on Profound Medical in the last twelve months: Alliance Global Partners, Jefferies Financial Group Inc., Lake Street Capital, and Raymond James.
View the latest analyst ratings for PROF.

What is the current price target for Profound Medical?

4 Wall Street analysts have set twelve-month price targets for Profound Medical in the last year. Their average twelve-month price target is $12.63, suggesting a possible upside of 31.5%. Raymond James has the highest price target set, predicting PROF will reach $20.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $6.50 for Profound Medical in the next year.
View the latest price targets for PROF.

What is the current consensus analyst rating for Profound Medical?

Profound Medical currently has 1 hold rating, 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PROF will outperform the market and that investors should add to their positions of Profound Medical.
View the latest ratings for PROF.

What other companies compete with Profound Medical?

Other companies that are similar to Profound Medical include Quipt Home Medical, Pulse Biosciences, Bioventus, NeuroPace and TELA Bio. Learn More about companies similar to Profound Medical.

How do I contact Profound Medical's investor relations team?

Profound Medical's physical mailing address is 2400 SKYMARK AVENUE UNIT 6, MISSISSAUGA A6, L4W 5K5. The company's listed phone number is (647) 476-1350 and its investor relations email address is [email protected]. The official website for Profound Medical is www.profoundmedical.com. Learn More about contacing Profound Medical investor relations.